< Decisions on essential uses: laboratory and analytical uses Up one level Decision VIII/10: Actions by Parties to promote industry's participation on a smooth and efficient transition away from CFC-based MDIs > Decisions on essential uses: metered-dose inhalers MDIs Decision VIII/10: Actions by Parties to promote industry's participation on a smooth and efficient transition away from CFC-based MDIs Decision VIII/11: Measures to facilitate a transition by a Party from CFC-based MDIs Decision VIII/12: Information gathering on a transition to non-CFC treatments for asthma and chronic obstructive pulmonary disease for Parties not operating under Article 5 Decision IX/19: Metered-dose inhalers (MDIs) Decision IX/20: Transfer of essential-use authorizations for CFCs for MDIs Decision XII/2: Measures to facilitate the transition to chlorofluorocarbon-free metered-dose inhalers Decision XIII/9: Metered-dose inhaler (MDI) production Decision XIII/10: Further study of campaign production of CFCs for metered-dose inhalers (MDIs) Decision XIV/5: Global database and assessment to determine appropriate measures to complete the transition from chlorofluorocarbon metered-dose inhalers Decision XV/5: Promoting the closure of essential-use nominations for metered-dose inhalers Decision XVII/14: Difficulties faced by some Parties operating under paragraph 1 of Article 5 of the Montreal Protocol with respect to chlorofluorocarbons used in the manufacture of metered-dose inhalers Decision XVIII/16: Difficulties faced by some Article 5 Parties manufacturing metered-dose inhalers which use chlorofluorocarbons Decision XX/4: Campaign production of chlorofluorocarbons for metered-dose inhalers Decision XXXVI/6: Developments regarding metered-dose inhalers with low-global-warming-potential propellants < Decisions on essential uses: laboratory and analytical uses Up one level Decision VIII/10: Actions by Parties to promote industry's participation on a smooth and efficient transition away from CFC-based MDIs >
